EQT Life Sciences
Investment Details
Investor Type
Private Investment Firm
Asset Class Focus
Venture Capital, Private Equity
Stage Focus
Early Stage, Growth, Late Stage, Series A, Series B, Pre-IPO, Seed, Buyout
Geographical Focus
United States, United Kingdom, Germany, France, Italy, Denmark, Switzerland, Spain, Ireland, Austria, Netherlands, Hungary, Portugal, Sweden, Belgium, Greece, Norway, Finland, Poland, Czech Republic
Industries Focus
- Healthcare
- Life Sciences
- Healthcare Services
- Digital Health
- Pharmaceuticals
- Medical Devices
- Diagnostics
- Biotechnology
- Oncology
- Neurology
- Cardiology
- Endocrinology
- Infectious Diseases
- Immunology
- Immuno-Oncology
- Rare Diseases
- Medical Technology
- Healthcare IT
- Biomedical Research
- Cardiovascular Diseases
- Genetically Defined Diseases
- Fibrosis
- Immunoscience
Investment Size:
5,000,000 to 100,000,000 USD
Investor Details Founded: 1988
EQT Life Sciences, formerly known as LSP, is a prominent European private investment firm focusing on the life sciences and healthcare sectors. With over €3.1 billion in assets under management, the firm has been instrumental in financing and developing innovative companies in biotechnology, pharmaceuticals, medical devices, and diagnostics. Their portfolio includes notable companies such as argenx, Crucell, and Qiagen.
The firm's investment strategy encompasses a range of stages, from seed and early-stage investments to late-stage and growth financing, including pre-IPO and buyout opportunities. They operate through multiple funds, each with a distinct investment focus: LSP 6 targets private early- to late-stage drug development and medical technology companies; LSP HEF 2 focuses on private late-stage medical technology companies with health and economic benefits; and LSP Public invests in public healthcare companies.
EQT Life Sciences is also an active contributor to the life sciences industry, holding roles as a founder and board member of the Oncode Institute and initiating the Dutch Venture Initiative (DVI). Their commitment to advancing healthcare innovation is further demonstrated through their substantial investments and strategic partnerships in the sector.
Requirements
- Innovative life sciences companies addressing unmet medical needs
- Strong management teams
- Scalable business models
- Potential for significant impact in the healthcare sector
- Innovative drug therapies
- Medical technologies addressing unmet medical needs
- Early-to-late-stage companies
- European and occasionally U.S. market focus
- Innovative life sciences and healthcare companies
Contact
[Official Website Hidden]
[LinkedIn Profile Hidden]
[HQ Location Hidden]
[Email Hidden]
Portfolio Companies
- argenx
- Crucell
- Qiagen
- Zealand Pharma
- KuDOS
- Movetis
- Neuravi
- Okairos
- Prosensa
- Rhein Biotech
- Pharming
- DNage
- Evommune
- Egle Therapeutics
- Hotspot
Mentioned In
-
$49.95
-
$39.95
-
$19.95
-
$24.95
-
$99.00
-
$19.95
-
$245.00
Claim this Investor
Are you an official representative of EQT Life Sciences?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim